CD19 and B-cell non-Hodgkin lymphoma: At the time of the workshop, there are three approved CD19-CAR-T cell platforms: tisagenlecleucel (Kymriah) for B cell lymphoma and pediatric B cell acute lymphocytic leukemia (ALL), axicabtagene ciloleucel (Yescarta) for B cell lymphoma, and brexucabtagene autoleucel (Tecartus) for mantle cell lymphoma (MCL) [16–18].